Table 3 |
|||
|
Adverse event and serious adverse event counts, percentages given in brackets, for 132 patients, who underwent total knee arthroplasty (TKA) before implementation of a critical pathway on TKA, versus 128 patients, who underwent TKA after path implementation |
|||
|
Before pathway implementation |
After pathway implementation |
Total |
|
|
adverse event |
n = 132 |
n = 128 |
n = 260 |
|
|
|||
|
Generalised seizure due to local anaesthetic intoxication |
0 (0) |
1 (1) |
1 (0) |
|
|
|||
|
DVT (lower leg) |
10 (8) |
6 (5) |
16 (6) |
|
|
|||
|
DVT (knee) |
4 (3) |
2 (2) |
6 (2) |
|
|
|||
|
DVT (thigh) |
0 (0) |
1 (1) |
1 (0) |
|
|
|||
|
Haematoma |
1 (1) |
3 (2) |
4 (2) |
|
|
|||
|
Wound healing problems |
1 (1) |
0 (0) |
1 (0) |
|
|
|||
|
Stiff knee |
0 (0) |
1 (1) |
1 (0) |
|
|
|||
|
Gastrointestinal bleeding |
0 (0) |
3 (2) |
3 (1) |
|
|
|||
|
Dekubital ulcer |
1 (1) |
2 (2) |
3 (1) |
|
|
|||
|
Postoperative cognitive disorder |
1 (1) |
0 (0) |
1 (0) |
|
|
|||
|
Speech disturbance and Hyperkinesia in Parkinson disease |
2 (2) |
1 (1) |
3 (1) |
|
|
|||
|
Postoperative hypertonia |
1 (1) |
3 (2) |
4 (2) |
|
|
|||
|
Cardiac blocks |
2 (2) |
2 (2) |
4 (2) |
|
|
|||
|
Diarrhoea |
1 (1) |
1 (1) |
2 (1) |
|
|
|||
|
Obstipation |
0 (0) |
1 (1) |
1 (0) |
|
|
|||
|
Erysipel |
1 (1) |
0 (0) |
1 (0) |
|
|
|||
|
Exanthema |
1 (1) |
3 (2) |
4 (2) |
|
|
|||
|
Otolaryngology consultation* |
2 (2) |
0 (0) |
2 (1) |
|
|
|||
|
Dentist consultation* |
1 (1) |
0 (0) |
1 (0) |
|
|
|||
|
Urinary tract infection |
0 (0) |
2 (2) |
2 (1) |
|
|
|||
|
Urologic consultation* |
1 (1) |
2 (2) |
3 (1) |
|
|
|||
|
Fall |
0 (0) |
2 (2) |
2 (1) |
|
|
|||
|
Posterior collum lesion (myelon)* |
0 (0) |
1 (1) |
1 (0) |
|
|
|||
|
Hyperhomocystinemia* |
0 (0) |
1 (1) |
1 (0) |
|
|
|||
|
Total AE |
30 (23) |
38 (29) |
68 (26) |
|
|
|||
|
serious adverse event |
|||
|
|
|||
|
Death during study period, unrelated |
1 (1) |
1 (1) |
2 (1) |
|
|
|||
|
Resuscitation (cardiological cause) |
1 (1) |
0 (0) |
1 (0) |
|
|
|||
|
Pulmonary embolism |
1 (1) |
0 (0) |
1 (0) |
|
|
|||
|
Revision for infection |
1 (1) |
3 (2) |
4 (2) |
|
|
|||
|
Revision for haematoma |
1 (1) |
0 (0) |
1 (0) |
|
|
|||
|
Closed mobilisation |
0 (0) |
3 (2) |
3 (1) |
|
|
|||
|
Opticusneuropathia |
0 (0) |
1 (1) |
1 (0) |
|
|
|||
|
Myocardial infarction |
0 (0) |
1 (1) |
1 (0) |
|
|
|||
|
Central vein thrombosis eye |
0 (0) |
1 (1) |
1 (0) |
|
|
|||
|
Subcutaneous infection belly (related to DVT prophylaxis) |
0 (0) |
1 (1) |
1 (0) |
|
|
|||
|
Total SAE |
5 (4) |
11 (9) |
16 (6) |
|
|
|||
|
* Adverse events unrelated to surgical treatment |
|||
|
Kirschner et al. Patient Safety in Surgery 2010 4:12 doi:10.1186/1754-9493-4-12 |
|||
